These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 9537247)

  • 1. Prognostic value of P53 gene mutations in a large series of node-negative breast cancer patients.
    Falette N; Paperin MP; Treilleux I; Gratadour AC; Peloux N; Mignotte H; Tooke N; Löfman E; Inganäs M; Bremond A; Ozturk M; Puisieux A
    Cancer Res; 1998 Apr; 58(7):1451-5. PubMed ID: 9537247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p53 mutation in plasma DNA and its prognostic value in breast cancer patients.
    Shao ZM; Wu J; Shen ZZ; Nguyen M
    Clin Cancer Res; 2001 Aug; 7(8):2222-7. PubMed ID: 11489795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor histology and stage but not p53, Her2-neu or cathepsin-D expression are independent prognostic factors in breast cancer patients.
    Korkolis DP; Tsoli E; Fouskakis D; Yiotis J; Koullias GJ; Giannopoulos D; Papalambros E; Nikiteas NI; Spiliopoulou CA; Patsouris E; Asimacopoulos P; Gorgoulis VG
    Anticancer Res; 2004; 24(3b):2061-8. PubMed ID: 15274401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of p53 gene mutation by polymerase chain reaction-single strand conformation polymorphism provides independent prognostic information in node-negative breast cancer.
    Iacopetta B; Grieu F; Powell B; Soong R; McCaul K; Seshadri R
    Clin Cancer Res; 1998 Jul; 4(7):1597-602. PubMed ID: 9676832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of mutations to different structural and functional regions of the p53 gene in breast cancer.
    Powell B; Soong R; Iacopetta B; Seshadri R; Smith DR
    Clin Cancer Res; 2000 Feb; 6(2):443-51. PubMed ID: 10690522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relevance of the expression of bcl-2 in combination with p53 as a prognostic factor in breast cancer.
    Jansen RL; Joosten-Achjanie SR; Volovics A; Arends JW; Hupperets PS; Hillen HF; Schouten HC
    Anticancer Res; 1998; 18(6A):4455-62. PubMed ID: 9891509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutant p53 protein overexpression in women with ipsilateral breast tumor recurrence following lumpectomy and radiation therapy.
    Turner BC; Gumbs AA; Carbone CJ; Carter D; Glazer PM; Haffty BG
    Cancer; 2000 Mar; 88(5):1091-8. PubMed ID: 10699900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma: 10-year follow up data.
    Goffin JR; Chappuis PO; Bégin LR; Wong N; Brunet JS; Hamel N; Paradis AJ; Boyd J; Foulkes WD
    Cancer; 2003 Feb; 97(3):527-36. PubMed ID: 12548593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patterns of p53 gene mutations in head and neck cancer: full-length gene sequencing and results of primary radiotherapy.
    Saunders ME; MacKenzie R; Shipman R; Fransen E; Gilbert R; Jordan RC
    Clin Cancer Res; 1999 Sep; 5(9):2455-63. PubMed ID: 10499619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognostic value of p53 immunostaining in node-negative breast carcinoma.
    Soontrapornchai P; Chanvitan A; Koontongkaew S; Sunpaweravong S
    J Med Assoc Thai; 2007 Sep; 90(9):1833-8. PubMed ID: 17957927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bcl-2 expression correlates with lymphovascular invasion and long-term prognosis in breast cancer.
    Neri A; Marrelli D; Roviello F; DeMarco G; Mariani F; DeStefano A; Megha T; Caruso S; Corso G; Cioppa T; Pinto E
    Breast Cancer Res Treat; 2006 Sep; 99(1):77-83. PubMed ID: 16541314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of uPA and p53 accumulation measured by quantitative biochemical assays in 1245 primary breast cancer patients: a multicentre study.
    Broët P; Spyratos F; Romain S; Quillien V; Daver A; Ricolleau G; Rallet A; Toulas C; Asselain B
    Br J Cancer; 1999 May; 80(3-4):536-45. PubMed ID: 10408864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multivariate analysis of bcl-2, apoptosis, P53 and HER-2/neu in breast cancer: a short-term follow-up.
    el-Ahmady O; el-Salahy E; Mahmoud M; Wahab MA; Eissa S; Khalifa A
    Anticancer Res; 2002; 22(4):2493-9. PubMed ID: 12174951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The expression of vascular endothelial growth factor correlates with mutant p53 and poor prognosis in human breast cancer.
    Linderholm BK; Lindahl T; Holmberg L; Klaar S; Lennerstrand J; Henriksson R; Bergh J
    Cancer Res; 2001 Mar; 61(5):2256-60. PubMed ID: 11280795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical characteristics and prognostic factors of female breast cancer patients with 10 or more positive lymph nodes: a report of 128 patients].
    Guan Y; Xu BH; Li Q; Zhang P; Zhao LM; Yuan P; Wang JY
    Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(2):77-81. PubMed ID: 18353207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of Bcl-2 and p53 expression in primary breast tumors and corresponding metastatic lymph nodes.
    Arun B; Kilic G; Yen C; Foster B; Yardley D; Gaynor R; Ashfaq R
    Cancer; 2003 Dec; 98(12):2554-9. PubMed ID: 14669273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.
    Olivier M; Langerød A; Carrieri P; Bergh J; Klaar S; Eyfjord J; Theillet C; Rodriguez C; Lidereau R; Bièche I; Varley J; Bignon Y; Uhrhammer N; Winqvist R; Jukkola-Vuorinen A; Niederacher D; Kato S; Ishioka C; Hainaut P; Børresen-Dale AL
    Clin Cancer Res; 2006 Feb; 12(4):1157-67. PubMed ID: 16489069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination.
    Yu H; Levesque MA; Clark GM; Diamandis EP
    Br J Cancer; 1999 Oct; 81(3):490-5. PubMed ID: 10507775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polyadenylate polymerase enzymatic activity in mammary tumor cytosols: A new independent prognostic marker in primary breast cancer.
    Scorilas A; Talieri M; Ardavanis A; Courtis N; Dimitriadis E; Yotis J; Tsiapalis CM; Trangas T
    Cancer Res; 2000 Oct; 60(19):5427-33. PubMed ID: 11034084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.